Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I7BL
|
||||
| Former ID |
DNC008409
|
||||
| Drug Name |
ARISTEROMYCIN
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Terminated | [546315] | ||
| Formula |
C11H15N5O3
|
||||
| Canonical SMILES |
C1C(C(C(C1N2C=NC3=C2N=CN=C3N)O)O)CO
|
||||
| InChI |
1S/C11H15N5O3/c12-10-7-11(14-3-13-10)16(4-15-7)6-1-5(2-17)8(18)9(6)19/h3-6,8-9,17-19H,1-2H2,(H2,12,13,14)/t5-,6-,8-,9+/m1/s1
|
||||
| InChIKey |
UGRNVLGKAGREKS-GCXDCGAKSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosylhomocysteinase | Target Info | Inhibitor | [529335] | |
| Adenosine A2a receptor | Target Info | Inhibitor | [525783] | ||
| Adenosine A1 receptor | Target Info | Inhibitor | [525783] | ||
| KEGG Pathway | Cysteine and methionine metabolism | ||||
| Metabolic pathwayshsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholismhsa04022:cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| WikiPathways | Metabolism of amino acids and derivatives | ||||
| Trans-sulfuration and one carbon metabolism | |||||
| One Carbon Metabolism | |||||
| Trans-sulfuration pathway | |||||
| Phase II conjugation | |||||
| Folate MetabolismWP80:Nucleotide GPCRs | |||||
| Monoamine Transport | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| References | |||||
| Ref 525783 | J Med Chem. 2000 Jun 1;43(11):2196-203.Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. | ||||
| Ref 529335 | Bioorg Med Chem. 2008 Apr 1;16(7):3809-15. Epub 2008 Jan 30.Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.